Trial Profile
A Phase I/II Study of TS-1, Irinotecan and Cisplatin for Patients With Advanced or Metastatic NSLC
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 27 Feb 2017
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary) ; Gimeracil/oteracil/tegafur (Primary) ; Irinotecan (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 09 Jul 2010 Planned end date changed from 1 Dec 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.
- 09 Apr 2009 New trial record